FLT1 has been evaluated as a target in other cancers (e.g., acute myeloid leukemia, leukemia, and chronic lymphocytic leukemia) and has been reported to be an important gene product in B-ALL [30,33,71,72]. This evidence concerns the gene FLT1 and B-cell chronic lymphocytic leukemia.